This clinical review addresses common questions primary care providers face regarding pharmacologic management of obesity. It emphasizes that pharmacotherapy should be considered for adults with a BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities, in conjunction with lifestyle interventions. The article reviews FDA-approved medications available at the time, including orlistat,
